Moderna, Inc. (NASDAQ:MRNA) is one of These 10 Stocks Are Making Big Moves. Moderna Inc. jumped by 8.83 percent on Tuesday to ...

Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when ...

The capped upside and unlimited downside risk make MRNY unattractive unless Moderna's share price stabilizes and recovers ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

Short sellers started to panic in recent days. Moderna (MRNA), which has a short interest of 16.44%, might benefit from two ...

“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...

In a report released today, Myles Minter from William Blair maintained a Hold rating on Moderna. The company’s shares closed last Thursday at $30.49. Don’t Miss TipRanks’ Ha ...

On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...

U.S-based copper mining company Freeport-McMoRan Inc. FCX gained 2.5% on Trump’s tariff threats on imported copper. Shares of Moderna, Inc. MRNA gained 8.8% on leading medical organizations filing a ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.